Dr. Bodi Zhang currently serves Chief Strategy Officer of Thorne HealthTech. Previously, Dr. Bodi Zhang has served as Chief Science Officer for Onegevity Health, LLC from January 2018 until its merger with our company in March 2021. Prior to his current role, Dr. Zhang served as Vice President, Corporate and Medical Strategy from January 2015 to 2018, and as General Manager, Strategic Alliance from January 2013 to 2015. Prior to joining our company, Dr. Zhang worked at Deallus Group, a global healthcare consultancy. Prior to the Deallus Group, Dr. Zhang was a Research Assistant Professor of Pharmacology at Tufts University, Boston. As a scientist, Bodi’s research focused on autoimmune diseases and published top-tier research publications, including in Proceedings of the National Academy of Sciences, The Journal of Allergy and Clinical Immunology and Nature Reviews. Dr. Zhang holds a Ph.D in Pharmacology and Biochemistry from Tufts University, Boston, an M.P.H in healthcare management from Harvard University, Boston and a M.D. from Peking University, China.